Biopharmaceutical company specializing in the development and commercialization of treatments for central nervous system disorders.
ACADIA Pharmaceuticals Inc., a prominent biopharmaceutical enterprise headquartered in San Diego, California, is dedicated to advancing innovative therapies that address critical unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company's flagship product, NUPLAZID (pimavanserin), is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis, offering a crucial therapeutic option in this challenging condition. ACADIA's robust pipeline includes Trofinetide, a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1, currently under development for the treatment of Rett Syndrome.
ACADIA Pharmaceuticals is also actively progressing Pimavanserin through the Phase III ADVANCE-2 study, evaluating its efficacy in addressing the negative symptoms of schizophrenia. Additionally, the company is advancing ACP-204 for the treatment of Alzheimer's disease psychosis, along with antisense oligonucleotide programs and other initiatives targeting neuropsychiatric symptoms.
The company's strategic colaborations strengthen its innovation capabilities significantly. ACADIA has entered into a license agreement with Neuren Pharmaceuticals Limited for the development and commercialization of Trofinetide across multiple indications, including Rett syndrome. Furthermore, a collaboration with Stoke Therapeutics, Inc. aims to discover, develop, and commercialize RNA-based medicines for severe and rare genetic neurodevelopmental diseases of the CNS.
Founded in 1993 as Receptor Technologies, Inc. and subsequently rebranded in 1997, ACADIA Pharmaceuticals continues to drive forward with a mission to transform the treatment landscape for CNS disorders and rare diseases. Through a steadfast commitment to scientific rigor and patient-centric innovation, ACADIA remains at the forefront of pioneering therapies that offer hope and improve outcomes for individuals facing challenging neurological conditions.